A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€13.43M
Enterprise Value€109.16
Total Cash (Recent Filing)€2.87M
Total Debt (Recent Filing)€595.00K
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€2.91M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery modest leverage reduces near-term solvency pressure and gives aXichem more financial flexibility while it develops its commercial pipeline, although ongoing losses could erode this cushion.
Proprietary Specialty-Chemicals PlatformOwnership and development of a focused phenylcapsaicin platform can support differentiated specialty-chemical products and create repeatable commercialization opportunities if regulatory and customer adoption hurdles are overcome.
Multiple Commercialization PathsPotential sales across feed supply chains, finished products, licensing, and collaborations provide avenues to diversify monetization beyond a single product format, though the pack does not confirm significant contracts or recurring licensing revenue.
Bears Say
Declining And Volatile RevenueA shrinking and inconsistent revenue base indicates that product adoption and commercial scale remain unproven. This limits operating leverage and makes it harder to absorb fixed costs or fund continued product development internally.
Severe UnprofitabilityNegative gross profit and very deep net losses show that current products do not yet support an economically viable operating model. Sustained margin weakness could consume equity and delay the transition to self-funded growth.
Persistent Cash BurnRecurring operating and free-cash-flow deficits increase dependence on external capital. If commercialization does not improve materially, funding needs may constrain development plans and weaken the otherwise strong low-debt balance sheet.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €13.43M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Nov 26, 2026 which is in 87 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on Aug 27, 2026. The company reported -€0.006 earnings per share for the quarter, beating the consensus estimate of -€0.013 by €0.007.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.006 in its last earnings report, beating expectations of -€0.013. Following the earnings report the stock price went up 2.538%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Hexpol AB
―
Nexam Chemical Holding AB
―
Polygiene AB
―
OrganoClick AB
―
Photocat A/S
―